[Communication and transparency concerning risk-benefit analysis in public health: the example of medication].
As far as communication of the evaluation of risk benefit assessment of medications is concerned, validated and interpreted data only have to be taken into account. Free access to information by the public has to be considered seriously and there is now a real and strong demand. This situation has to be viewed in parallel with the huge development of websites communicating information on health issues. This report summarizes the discussion between the authorities and pharmaceutical companies and reports the different concrete proposals that emerged.
Lehner
J P
JP
Laboratoires Sanofi-Synthélabo, 22 ave Galilée, BP 82, 92355 Le Plessis Robinson, France.
Meyer
F
F
Juillet
Y
Y
D016907:Adverse Drug Reaction Reporting Systems; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D003258:Consumer Behavior; D030881:Disclosure; D004341:Drug Evaluation; D004345:Drug Industry; D004346:Drug Information Services / Q000592:standards; D064420:Drug-Related Side Effects and Adverse Reactions; D005602:France; D006801:Humans; D020407:Internet; D008402:Mass Media; D010353:Patient Education as Topic; D018570:Risk Assessment